CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CytomX's Varsetatug Masetecan Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
Nevada Sunrise Enters into Earn-in Option Agreement for the Fivemile Gold Project, Cortez Mining District, Nevada
Sun Summit Outlines 2026 Exploration Plan for the Theory Copper-Gold Project, Toodoggone Mining District, BC
